➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Moodys
Johnson and Johnson
Merck

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

DAPTOMYCIN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Daptomycin, and when can generic versions of Daptomycin launch?

Daptomycin is a drug marketed by Accord Hlthcare, Be Pharms, Dr Reddys, Fresenius Kabi Usa, Hisun Pharm Hangzhou, Hospira Inc, Jiangsu Hengrui Med, Mylan Labs Ltd, Sagent Pharms Inc, Teva Pharms Usa, and Xellia Pharms Aps. and is included in sixteen NDAs.

The generic ingredient in DAPTOMYCIN is daptomycin. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Daptomycin

A generic version of DAPTOMYCIN was approved as daptomycin by HOSPIRA INC on September 12th, 2014.

  Free Forever Trial

Drug patent expirations by year for DAPTOMYCIN
Drug Prices for DAPTOMYCIN

See drug prices for DAPTOMYCIN

Recent Clinical Trials for DAPTOMYCIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
University Hospital, CaenPhase 1
Vancouver Island Health AuthorityPhase 4

See all DAPTOMYCIN clinical trials

Pharmacology for DAPTOMYCIN
Medical Subject Heading (MeSH) Categories for DAPTOMYCIN
Paragraph IV (Patent) Challenges for DAPTOMYCIN
Tradename Dosage Ingredient NDA Submissiondate
CUBICIN POWDER;INTRAVENOUS daptomycin 021572 2008-11-19
CUBICIN RF POWDER;INTRAVENOUS daptomycin 021572 2008-11-19

US Patents and Regulatory Information for DAPTOMYCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 211961-001 Jun 24, 2019 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Jiangsu Hengrui Med DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 212022-001 Aug 22, 2019 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Fresenius Kabi Usa DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 206077-001 Apr 11, 2018 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Moodys
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.